和鉑醫藥-B(02142.HK)預計年度盈利約730萬元-2200萬元 現金溢利達到歷史新高
格隆匯2月14日丨和鉑醫藥-B(02142.HK)宣佈,根據對集團截至2024年12月31日止年度未經審計綜合管理賬目之初步審閱,預期集團於報告期間的溢利將介乎人民幣730萬元至人民幣2200萬元。於報告期間,公司的現金溢利達到人民幣2.20億元的歷史新高,顯現蓬勃的業務勢頭及高運營效率。
集團的可持續盈利能力主要由以下因素所驅動:(i)通過與全球製藥公司及領先的生物技術公司持續保持戰略合作夥伴關係,其獨特業務模式加速增長;(ii)收入的經常性部分於2024年不斷增長,包括基於平臺的研究收入及隨着合作項目逐漸成熟而收到來自合作夥伴的里程碑付款;以及(iii)本集團有效的成本控制及高效運營管理。
在我們專有的Harbour Mice®平臺及既定的獨特業務模式的支持下,集團現正加速轉型,成爲可持續盈利的全球生物技術引擎。通過與全球跨國公司和領先的生物技術公司合作,我們目前在全球已有超過19個分子進入IND階段,這成功地認可並驗證了我們平臺的價值。
於2025年,公司於公開市場已合共購回814.6萬股股份,總值近3000萬港元。此進展反映了公司對其業務前景及展望的信心,同時表明公司管理層認爲當前估值與公司的內在價值脫節。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.